News | July 21, 2022
Syngene reports revenue from operations up 8% in Q1 FY 23
Company raises the annual revenue guidance from mid-teens to high teens
Company raises the annual revenue guidance from mid-teens to high teens
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
Syngene's collaboration with Zoetis started in 2011
Post this currently only Risperidone orally disintegrating tablets are allowed for import into the US from the Roorkee facility.
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
The product will be launched by NATCO's commercial partner Viatris.
ICICI Direct expects revenue CAGR of 35.6% over FY22-FY24E mainly due to the consolidation of Viatris business and they expect EBITDA margin expansion of 230bps and earnings CAGR of 64.8% over FY22-FY24E
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
Subscribe To Our Newsletter & Stay Updated
